6 results on '"Goulden, N"'
Search Results
2. Group cognitive stimulation therapy versus usual care for people with intellectual disabilities and dementia (CST-IDD) in the UK: protocol for a mixed-methods feasibility randomised controlled trial.
- Author
-
Ali A, Aguirre E, Carter J, Hoare S, Brackley K, Goulden N, Hoare Z, Clarke CS, Charlesworth G, Acton D, and Spector A
- Subjects
- Humans, Quality of Life, Feasibility Studies, Cognition, United Kingdom, Cost-Benefit Analysis, Randomized Controlled Trials as Topic, Dementia therapy, Dementia psychology, Intellectual Disability therapy
- Abstract
Introduction: The prevalence of dementia is almost five times higher in people with intellectual disabilities compared with the general population. However, evidence-based treatments for this population are lacking, as most randomised controlled trials for dementia interventions have not included people with intellectual disabilities. Cognitive stimulation therapy (CST) has a robust evidence base in the general dementia population, consistently showing benefits to cognition, quality of life and being cost-effective. We are conducting a mixed-methods feasibility trial of group CST for people with intellectual disabilities and dementia, to determine if a future definitive randomised controlled trial is feasible., Methods and Analysis: Fifty individuals with intellectual disabilities and dementia will be randomised to either the intervention arm (14 sessions of group CST plus treatment as usual) or the control arm (treatment as usual). Randomisation will occur after informed consent has been obtained and baseline assessments completed. Each arm will have 25 participants, with the intervention arm divided into five or more CST groups with three to five participants in each. The outcomes will be feasibility of recruitment, acceptability and adherence of the intervention, suitability of study outcome measures and feasibility of collecting resource use data. Quantitative and qualitative approaches, including semistructured interviews with group participants, carers and group facilitators, will be employed to assess these outcomes., Ethics and Dissemination: This study has been approved by Essex REC (Ref: 21/EE/027) and the HRA ethical approval process through the Integrated Research Application System (IRAS ID: 306 756). We plan to publish the results in peer-reviewed journals and conferences as well as provide feedback to funders, sponsors and study participants., Trial Registration Number: ISRCTN88614460., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
3. Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT.
- Author
-
Poolman M, Roberts J, Wright S, Hendry A, Goulden N, Holmes EA, Byrne A, Perkins P, Hoare Z, Nelson A, Hiscock J, Hughes D, O'Connor J, Foster B, Reymond L, Healy S, Lewis P, Wee B, Johnstone R, Roberts R, Parkinson A, Roberts S, and Wilkinson C
- Subjects
- Adult, Feasibility Studies, Female, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Surveys and Questionnaires, Terminal Care, United Kingdom, Caregivers education, Caregivers psychology, Home Care Services, Injections, Subcutaneous nursing, Medication Adherence, Terminally Ill
- Abstract
Background: Most people who are dying want to be cared for at home, but only half of them achieve this. The likelihood of a home death often depends on the availability of able and willing lay carers. When people who are dying are unable to take oral medication, injectable medication is used. When top-up medication is required, a health-care professional travels to the dying person's home, which may delay symptom relief. The administration of subcutaneous medication by lay carers, although not widespread UK practice, has proven to be key in achieving better symptom control for those dying at home in other countries., Objectives: To determine if carer administration of as-needed subcutaneous medication for common breakthrough symptoms in people dying at home is feasible and acceptable in the UK, and if it would be feasible to test this intervention in a future definitive randomised controlled trial., Design: We conducted a two-arm, parallel-group, individually randomised, open pilot trial of the intervention versus usual care, with a 1 : 1 allocation ratio, using convergent mixed methods., Setting: Home-based care without 24/7 paid care provision, in three UK sites., Participants: Participants were dyads of adult patients and carers: patients in the last weeks of their life who wished to die at home and lay carers who were willing to be trained to give subcutaneous medication. Strict risk assessment criteria needed to be met before approach, including known history of substance abuse or carer ability to be trained to competency., Intervention: Intervention-group carers received training by local nurses using a manualised training package., Main Outcome Measures: Quantitative data were collected at baseline and 6-8 weeks post bereavement and via carer diaries. Interviews with carers and health-care professionals explored attitudes to, experiences of and preferences for giving subcutaneous medication and experience of trial processes. The main outcomes of interest were feasibility, acceptability, recruitment rates, attrition and selection of the most appropriate outcome measures., Results: In total, 40 out of 101 eligible dyads were recruited (39.6%), which met the feasibility criterion of recruiting > 30% of eligible dyads. The expected recruitment target (≈50 dyads) was not reached, as fewer than expected participants were identified. Although the overall retention rate was 55% (22/40), this was substantially unbalanced [30% (6/20) usual care and 80% (16/20) intervention]. The feasibility criterion of > 40% retention was, therefore, considered not met. A total of 12 carers (intervention, n = 10; usual care, n = 2) and 20 health-care professionals were interviewed. The intervention was considered acceptable, feasible and safe in the small study population. The context of the feasibility study was not ideal, as district nurses were seriously overstretched and unfamiliar with research methods. A disparity in readiness to consider the intervention was demonstrated between carers and health-care professionals. Findings showed that there were methodological and ethics issues pertaining to researching last days of life care., Conclusion: The success of a future definitive trial is uncertain because of equivocal results in the progression criteria, particularly poor recruitment overall and a low retention rate in the usual-care group. Future work regarding the intervention should include understanding the context of UK areas where this has been adopted, ascertaining wider public views and exploring health-care professional views on burden and risk in the NHS context. There should be consideration of the need for national policy and of the most appropriate quantitative outcome measures to use. This will help to ascertain if there are unanswered questions to be studied in a trial., Trial Registration: Current Controlled Trials ISRCTN11211024., Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 25. See the NIHR Journals Library website for further project information., Competing Interests: Anthony Byrne reports grants from Marie Curie (London, UK), Health and Care Research Wales, the End of Life Board for Wales and the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme outside the submitted work; he is also a member of the End of Life Board for Wales, which is responsible to the Welsh Government for developing and implementing strategy for end-of-life care in Wales. Bee Wee reports that she is National Clinical Director for End of Life Care, Chairperson of the National Institute for Health and Care Excellence Quality Standards Advisory Committee and has a NIHR-funded grant outside the submitted work. She has also received royalties for a book published by Oxford University Press (Oxford, UK). Dyfrig Hughes reports that he was a member of the HTA Programme Pharmaceuticals Panel (2008–12) and member of the HTA Programme Clinical Evaluation and Trials Board (2010–16). Marlise Poolman was a member of the HTA Prioritisation Committee: Integrated Community Health and Social Care (A) from 2013 to 2019. Zoe Hoare reports that she is an associate member of NIHR Health Services and Delivery Research board. Clare Wilkinson reports that she was chairperson of the HTA Commissioning Panel – Primary Care, Community, Preventive Interventions (2013–18) and a member of the HTA Rapid and Add-0n Trials Board (2012–13).
- Published
- 2020
- Full Text
- View/download PDF
4. Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC).
- Author
-
Williams NH, Jenkins A, Goulden N, Hoare Z, Hughes DA, Wood E, Foster NE, Walsh D, Carnes D, Sparkes V, Hay EM, Isaacs J, Konstantinou K, Morrissey D, Karppinen J, Genevay S, and Wilkinson C
- Subjects
- Adalimumab adverse effects, Anti-Inflammatory Agents adverse effects, Combined Modality Therapy, Contracts, Disability Evaluation, Humans, Injections, Subcutaneous, Pain Measurement, Patient Selection, Research Support as Topic, Sciatica diagnosis, Sciatica immunology, Sciatica physiopathology, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Tumor Necrosis Factor-alpha immunology, United Kingdom, Adalimumab administration & dosage, Anti-Inflammatory Agents administration & dosage, Early Termination of Clinical Trials economics, Physical Therapy Modalities adverse effects, Sciatica drug therapy
- Abstract
Background: Adalimumab, a biological treatment targeting tumour necrosis factor α, might be useful in sciatica. This paper describes the challenges faced when developing a new treatment pathway for a randomised controlled trial of adalimumab for people with sciatica, as well as the reasons why the trial discussed was stopped early., Methods: A pragmatic, parallel group, randomised controlled trial with blinded (masked) participants, clinicians, outcome assessment and statistical analysis was conducted in six UK sites. Participants were identified and recruited from general practices, musculoskeletal services and outpatient physiotherapy clinics. They were adults with persistent symptoms of sciatica of 1 to 6 months' duration with moderate to high level of disability. Eligibility was assessed by research physiotherapists according to clinical criteria, and participants were randomised to receive two doses of adalimumab (80 mg then 40 mg 2 weeks later) or saline placebo subcutaneous injections in the posterior lateral thigh. Both groups were referred for a course of physiotherapy. Outcomes were measured at baseline, 6-week, 6-month and 12-month follow-up. The main outcome measure was disability measured using the Oswestry Disability Index. The planned sample size was 332, with the first 50 in an internal pilot phase., Results: The internal pilot phase was discontinued after 10 months from opening owing to low recruitment (two of the six sites active, eight participants recruited). There were several challenges: contractual delays; one site did not complete contract negotiations, and two sites signed contracts shortly before trial closure; site withdrawal owing to patient safety concerns; difficulties obtaining excess treatment costs; and in the two sites that did recruit, recruitment was slower than planned because of operational issues and low uptake by potential participants., Conclusions: Improved patient care requires robust clinical research within contexts in which treatments can realistically be provided. Step changes in treatment, such as the introduction of biologic treatments for severe sciatica, raise complex issues that can delay trial initiation and retard recruitment. Additional preparatory work might be required before testing novel treatments. A randomised controlled trial of tumour necrosis factor-α blockade is still needed to determine its cost-effectiveness in severe sciatica., Trial Registration: Current Controlled Trials, ISRCTN14569274 . Registered on 15 December 2014.
- Published
- 2018
- Full Text
- View/download PDF
5. Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial.
- Author
-
Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, Patrick K, Hancock J, Samarasinghe S, Linch DC, Moorman AV, Goulden N, Vora A, and Mansour MR
- Subjects
- Child, Female, Humans, Kaplan-Meier Estimate, Male, Polymorphism, Single Nucleotide, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma therapy, Prognosis, United Kingdom, Biomarkers, Tumor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma mortality, Quantitative Trait Loci, Sequence Deletion
- Published
- 2018
- Full Text
- View/download PDF
6. Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003.
- Author
-
Sellar RS, Rowntree C, Vora AJ, Furness CL, Goulden N, Mitchell C, Moorman AV, and Hough R
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Female, Humans, Male, Neoplasm, Residual, Recurrence, Salvage Therapy, Survival Rate, United Kingdom epidemiology, Young Adult, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma mortality
- Abstract
Outcomes for teenage and young adult (TYA) patients with acute lymphoblastic leukaemia (ALL) who relapse on contemporary risk-adapted paediatric protocols are largely unknown and there is no consensus on optimal salvage strategies. We assessed the treatment and outcome of TYA patients (aged 16-24 years) recruited to the UKALL2003 trial, who relapsed following attainment of complete morphological remission. Forty-two of 223 patients (18·8%) relapsed, the majority (n = 26, 62%) on treatment. Thirty-eight (90%) patients received salvage treatment, with 22 (58%) achieving second remission (CR2) and 21 patients receiving an allogeneic haematopoietic cell transplant (alloHSCT). Post-relapse outcomes were poor with a 5-year overall survival (OS) of 23% (95% confidence interval; 11-37%). Outcomes for patients relapsing on active treatment were inferior to those relapsing after completing treatment (5-year OS 9% vs. 52%, log-rank P = 0·001). No patient with B cell ALL relapsing on treatment was alive at the end of the study period. TYA patients with ALL who relapse on the UK paediatric protocol, UKALL2003, are largely unsalvageable with conventional approaches aimed at achieving CR2 followed by alloHSCT. Future efforts should be aimed at identifying those patients who are destined to relapse and exploring novel treatment approaches for this high-risk group and for those who do relapse., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.